So it’s very, very inconvenient. And they have to continue getting echocardiograms for the duration of that therapy. And then one more if they do choose to discontinue it. We’ve heard numerous instances across the country where echocardiograms are available, but they’re not readily available. There’ll be a waiting list in order to obtain one. I think it’s a significant challenge for patients. And we feel really confident in the approach of interaction with 5-HT2C, but you’ve got to do it in a way where it’s going to be safe and convenient for patients. We think that’s what LP352 has the promise of
Kevin Lind: Congrats to everyone involved in the fenfluramine approval and launch. I don’t want to speak negatively about them. But UCB just mentioned that they expect peak sales of that molecule to be about €800 million. And if you kind of back into what that translates to from a patient perspective, patient number perspective, based on their current pricing, it doesn’t appear that UCB expects to even get a large percentage of the Dravet market, let alone if you add the Dravet market on top of the Lennox-Gastaut market. And so, we’re not hearing a lot of feedback from the community. I don’t have any patients for you because all of my patients are on fenfluramine. We’re not hearing a lot of feedback that, oh, my gosh, I don’t know how you’re going to beat fenfluramine in the marketplace.
That gives us tremendous hope for our molecule and hope for these patients to make these parents, these caregivers’ lives easier. And we think a safer molecule does that. And it’s back to that conversation that we were having based on Josh’s question, which is, do we even need a switch study. And I think that’s going to be an interesting one along the way. And the good news is we can see this specific data and see the continued launch trajectory of fenfluramine and then make that decision down the road. But fenfluramine has now been on the market for two-and-a-half years and the sales are what they are. And so, I think we’re not overly concerned about our ability to differentiate ourselves and hopefully have a preferred molecule on the market down the road.
Operator: Thank you. This concludes our Q&A session. I would now like to turn the conference back to Kevin for closing remarks.
Kevin Lind: Thanks, operator. And I want to thank everyone for joining the call today and for sharing in our enthusiasm in the Longboard story as we approach data readouts across our pipeline in the second half of this year. Have a great day.
Brandi Roberts: Thanks.
Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Everyone, have a great day.